Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.63 |
| ▸ | CTSK | P43235 | 14/20 | 0.63 |
| ▸ | CTSB | P07858 | 4/20 | 0.62 |
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9259835 | 1.00 | CTSS (0.63) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL18930492 | 1.00 | CTSS (0.63) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL1350138 | 0.88 | PTPN1 (0.62) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL3450109 | 0.88 | PTPN1 (0.62) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL31524193 | 0.88 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL1350140 | 0.88 | PTPN1 (0.62) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL15084091 | 0.86 | CTSS (0.58) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL18920552 | 0.86 | CTSS (0.58) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL16935721 | 0.86 | CTSS (0.58) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL18930696 | 0.86 | CTSS (0.58) | CTSSCTSKCTSBCTSLPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2020-10-29 | — | — | US | disclosed |
| WO-2017190048-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | X-CHEM, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| EP-2758398-B1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL]-2-AZABICYCLO [2.2.1]HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| WO-2013041497-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-28 | — | — | WO | disclosed |
| US-5412145-A | P2'-modified hydroxamic acid collagenase inhibitors | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1995-05-02 | — | — | US | disclosed |
| US-5300674-A | P2'-modified hydroxamic acid collagenase inhibitors | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | CTSS 2152/4885CTSK 1208/4885CTSB 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.